Bionano Genomics, Inc. (NASDAQ:BNGO) is set to announce second quarter earning results on Thursday 13th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, BNGO to report 2Q20 loss of $ 0.09 per share.
For the full year, analysts anticipate top line of $ 6.89 million, while looking forward to loss of $ 0.42 per share bottom line.
Previous Quarter Performance
Bionano Genomics, Inc. reported loss for the first quarter of $ 0.15 per share, from the revenue of $ 1.14 million. The quarterly revenues declined 28.30 percent compared with the same quarter last year. According to street consensus, BNGO was expected to report 1Q20 loss of $ 0.21 per share from revenue of $ 1.70 million. The bottom line results beat street analysts by $ 0.06 or 28.57 percent, at the same time, top line results fell short of analysts by $ 0.56 million or 32.94 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Bionano Genomics, Inc.
Stock Performance
According to the previous trading day, closing price of BNGO was $ 0.77, representing a 208.00 % increase from the 52 week low of $ 0.25 and a 83.62 % decrease over the 52 week high of $ 4.70.
The company has a market capital of $ 105.37 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BNGO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
